» Authors » Oleksandr Petrenko

Oleksandr Petrenko

Explore the profile of Oleksandr Petrenko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 49
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Semmler G, Baumgartner C, Metz M, Gensluckner S, Habisch H, Hofer H, et al.
J Clin Endocrinol Metab . 2025 Mar; PMID: 40037526
Context: Tangier disease (TD) is a rare, autosomal recessive genetic disorder associated with a deficiency in cellular cholesterol export leading to cholesterol accumulation in peripheral tissues. With approximately 150 described...
2.
Trufanova N, Hubenia O, Kot Y, Trufanov O, Kovalenko I, Kot K, et al.
Biopreserv Biobank . 2024 Dec; PMID: 39723454
Human mesenchymal stromal cells (MSCs) are attractive for both medical practice and biomedical research. Nonfreezing short-term storage may provide safe and simple transportation and promote the practical use of MSCs....
3.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
United European Gastroenterol J . 2024 Dec; PMID: 39708052
Background: Portal hypertension (PH) resulting from static and dynamic intrahepatic changes drives liver-related complications even after removing the underlying aetiological factor. Objective: We investigated the impact of inflammation on the...
4.
Semmler G, Petrenko O, Lozano J, Shalaby S, Sanchez-Avila J, Marella N, et al.
JHEP Rep . 2024 Dec; 6(12):101208. PMID: 39624234
Background & Aims: Porto-sinusoidal vascular disorder (PSVD) is a rare and diagnostically challenging vascular liver disease. This study aimed to identify distinct metabolomic signatures in patients with PSVD or cirrhosis...
5.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
Dig Liver Dis . 2024 Sep; 57(2):450-458. PMID: 39343656
Background: Cirrhosis is associated with a proinflammatory environment. Aims: To analyse aetiology-specific inflammation patterns in compensated cirrhosis in animal models and patients. Methods: Portal pressure (PP), fibrosis (collagen proportionate area...
6.
Burghart L, Ferenci P, Petrenko O, Mandorfer M, Schwarz M, Gschwantler M, et al.
Aliment Pharmacol Ther . 2024 May; 60(2):257-266. PMID: 38798050
Background And Aims: Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH-related features on hepatic decompensation...
7.
Piven O, Pokrytiuk V, Kasianchuk N, Ostash B, Dekina S, Panchuk R, et al.
Cell Syst . 2024 Apr; 15(4):298-304. PMID: 38636455
We have asked Ukrainian scientists how they have been able to persist in pursuing their research since the beginning of the full-scale invasion of Ukraine by the Russian Federation in...
8.
Hofer B, Burghart L, Halilbasic E, Simbrunner B, Petrenko O, Mandorfer M, et al.
Aliment Pharmacol Ther . 2024 Apr; 59(9):1146-1147. PMID: 38591799
No abstract available.
9.
Petrenko O, Konigshofer P, Brusilovskaya K, Hofer B, Bareiner K, Simbrunner B, et al.
iScience . 2024 Mar; 27(3):109301. PMID: 38469563
Persistent liver injury triggers a fibrogenic program that causes pathologic remodeling of the hepatic microenvironment (i.e., liver fibrosis) and portal hypertension. The dynamics of gene regulation during liver disease progression...
10.
Hofer B, Burghart L, Halilbasic E, Simbrunner B, Petrenko O, Mandorfer M, et al.
Aliment Pharmacol Ther . 2024 Feb; 59(8):962-972. PMID: 38409879
Background: Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis. Aims: We explored the potential for recompensation in patients with decompensated primary biliary cholangitis (PBC) -...